# Higher Dose Weekly Topotecan In The Treatment Of Patients With Extensive Stage Small-Cell Lung Cancer

> **NCT00294190** · PHASE2 · COMPLETED · sponsor: **SCRI Development Innovations, LLC** · enrollment: 38 (actual)

## Conditions studied

- Small Cell Lung Cancer
- Carcinoma, Small Cell

## Interventions

- **DRUG:** Topotecan

## Key facts

- **NCT ID:** NCT00294190
- **Lead sponsor:** SCRI Development Innovations, LLC
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-02
- **Primary completion:** 2007-09
- **Final completion:** 2009-07
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2012-12-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00294190

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00294190, "Higher Dose Weekly Topotecan In The Treatment Of Patients With Extensive Stage Small-Cell Lung Cancer". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT00294190. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*